Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylic Acid SCHEMBL10765376 | 0.93 | NPSR1 (0.37) | NPSR1ALDH1A1TSHRMAPTGLO1 | |
| SCHEMBL10904258 | 0.85 | TSHR (0.39) | NPSR1ALDH1A1TSHRMAPTTHRB | |
| SCHEMBL1245379 | 0.83 | ALDH1A1 (0.37) | ALDH1A1TSHREGLN1 | |
| Methacrylic Acid SCHEMBL9147315 | 0.82 | THRB (0.38) | NPSR1ALDH1A1TSHRMAPTGLO1 | |
| Hydrochloric Acid SCHEMBL1562603 | 0.81 | THRB (0.42) | TSHRMAPTCYP2D6SMN1; SMN2THRB | |
| SCHEMBL5595771 | 0.80 | FFAR3 (0.35) | ALDH1A1TSHR | |
| SCHEMBL18169351 | 0.80 | FFAR3 (0.35) | ALDH1A1TSHR | |
| SCHEMBL432150 | 0.79 | NPSR1 (0.42) | NPSR1ALDH1A1TSHRMAPTGLO1 | |
| SCHEMBL14406989 | 0.79 | NPSR1 (0.45) | NPSR1ALDH1A1TSHRMAPTGLO1 | |
| Ammonia Solution, Strong SCHEMBL15128898 | 0.78 | NPSR1 (0.41) | NPSR1ALDH1A1TSHRMAPTGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121017-A1 | EXPANDABLE, MULTI-EXCIPIENT STRUCTURED DOSAGE FORM FOR PROLONGED DRUG RELEASE | Blaesi, Aron H. (CH) | 2023-01-25 | — | — | EP | claimed |
| US-20220304924-A1 | Expandable multi-excipient dosage form | BLAESI, ARON H. (US) | 2022-09-29 | — | — | US | claimed |
| WO-2021188742-A1 | EXPANDABLE, MULTI-EXCIPIENT STRUCTURED DOSAGE FORM FOR PROLONGED DRUG RELEASE | BLAESI ARON H (US) | 2021-09-23 | — | — | WO | claimed |
| WO-2009067684-A1 | MODIFIED RELEASE NIACIN FORMULATIONS | CAPRICORN PHARMA INC. (US) | 2009-05-28 | — | — | WO | claimed |
| US-20090130208-A1 | Modified release niacin formulations | CAPRICORN PHARMA INC. (US) | 2009-05-21 | — | — | US | claimed |
| EP-4121017-A1 | EXPANDABLE, MULTI-EXCIPIENT STRUCTURED DOSAGE FORM FOR PROLONGED DRUG RELEASE | Blaesi, Aron H. (CH) | 2023-01-25 | — | — | EP | disclosed |
| US-20220304924-A1 | Expandable multi-excipient dosage form | BLAESI, ARON H. (US) | 2022-09-29 | — | — | US | disclosed |
| US-11357730-B2 | Controlled activation ingestible identifier | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-06-14 | — | — | US | disclosed |
| WO-2021188742-A1 | EXPANDABLE, MULTI-EXCIPIENT STRUCTURED DOSAGE FORM FOR PROLONGED DRUG RELEASE | BLAESI ARON H (US) | 2021-09-23 | — | — | WO | disclosed |
| CN-110269838-A | Propane -1- sulfonic acid { 3- [5- (the chloro- phenyl of 4-) -1H- pyrrolo- [2,3-b] pyridine -3- carbonyl] -2,4- difluorophenyl }-amide compositions and application thereof | 豪夫迈罗氏公司 | 2019-09-24 | — | — | CN | disclosed |
| US-20190133958-A1 | CONTROLLED ACTIVATION INGESTIBLE IDENTIFIER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-05-09 | — | — | US | disclosed |
| US-10238604-B2 | Controlled activation ingestible identifier | PROTEUS DIGITAL HEALTH, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-1467207-A1 | SCREENING METHOD | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-0954292-B1 | PHARMACEUTICAL FORMULATIONS WITH DELAYED DRUG RELEASE | POLICHEM SA (LU) | 2003-07-02 | — | — | EP | disclosed |
| US-6190692-B1 | Time-specific controlled release capsule formulations and method of preparing same | BUSETTI CESARE (IT) | 2001-02-20 | — | — | US | disclosed |
| EP-0954293-A1 | TIME-SPECIFIC CONTROLLED RELEASE DOSAGE FORMULATIONS AND METHOD OF PREPARING SAME | Polin Industria Chimica S.p.A. (IT) | 1999-11-10 | — | — | EP | disclosed |
| US-5891474-A | Time-specific controlled release dosage formulations and method of preparing same | POLI INDUSTRIA CHIMICA, S.P.A. (IT) | 1999-04-06 | — | — | US | disclosed |
| US-5788987-A | TIME-SPECIFIC CONTROLLED RELEASE DOSAGE FORMULATION | POLI INDUSTRIA CHIMICA SPA (IT) | 1998-08-04 | — | — | US | disclosed |
| WO-1998032426-A1 | TIME-SPECIFIC CONTROLLED RELEASE DOSAGE FORMULATIONS AND METHOD OF PREPARING SAME | POLIN INDUSTRIA CHIMICA S.P.A. (IT) | 1998-07-30 | — | — | WO | disclosed |
| CN-1179102-A | 2-methyl-thieno-benzodiazepine * oral formulations | LILLY CO ELI (US) | 1998-04-15 | — | — | CN | disclosed |